Skip to main content
. Author manuscript; available in PMC: 2015 Nov 15.
Published in final edited form as: Clin Cancer Res. 2014 Sep 15;20(22):5808–5822. doi: 10.1158/1078-0432.CCR-14-0234

Figure 5. DNMT1 is the direct target of miR-148a in glioma.

Figure 5

A and B, the expression level of DNMT1 in IDH1WT and IDH1MUT GBM patients from the TCGA data set (A) and our validation patient cohort (B). C–F, DNMT1 expression was determined by qPCR (C and E) and Western Blot (D and F) in U251 cells transiently (C and D) and stably (E and F) overexpressing miR-148a. G, human DNMT1 3′-UTR region contain miR-148a binding sites and dural luciferase assays were conducted using DNMT1 wild type (WT) and mutant (MUT) 3′-UTR reporter constructs. H and I, gene expression of hypermethylated RBP1, CIDEB and DLC1 in glioma cell lines U251 (H) and T98G (I) overexpressing miR-148a was determined by qPCR. Data were standardized to EV which was set as 100%. J and K, qPCR analysis of gene expression level in U251 (J) or T98G (K) cells treated with DMSO or 5-aza-CdR for 72 hours. Data were standardized to vehicle control (DMSO) which was set as 100%. *, P<0.05; **, P<0.01; ***, P<0.001.